Evidence for Change: Health literacy
Friday, September 3, 2021
This first issue of our Evidence for Change series provides a brief, evidence-based overview of key behavioral science research that Atlantis Health applies in support of patients to achieve optimal health outcomes.
This issue looks at health literacy and the importance of considering this in developing effective support solutions for people living with long-term conditions.
Atlantis Health Engages University of Miami’s Michael H. Antoni, PhD
Monday, July 12, 2021
Atlantis Health, a pioneer and global leader in health psychology-based patient support programs, has engaged Michael H. Antoni, PhD to provide expertise for their broadened set of digital health solutions focused on cancer and other chronic diseases.
Delivering Improved Outcomes in Type 2 Diabetes With Personalized Support
Tuesday, June 15, 2021
Developed and evaluated by Atlantis Health New Zealand, the myMeds program for people living with type 2 diabetes demonstrates improved medication adherence, with program members reporting high satisfaction and positive health impact. Results were presented at the June 2021 virtual conference of the International Congress of Behavioral Medicine.
How Psychology and Technology Can Support Adherence and Other Health Behaviors
Monday, June 14, 2021
This one-hour video from a recent World Congress webinar features Atlantis Healthcare CEO Jonny Duder and US Country Manager Amy Parke along with Professor John Weinman of King's College London and our Northern Hemisphere Behavioral Science Lead. They discuss challenges that have particularly emerged from the COVID-19 pandemic, and how these can be addressed effectively using psychology and technology to bridge the gap.
The Shock of the New
Thursday, April 29, 2021
A chronic illness diagnosis can have significant psychological impacts on the person with the illness and on those who are close to them. Very often, they need to adjust to the new demands of treatment and lifestyle change. Personalized behavior change support that targets the most immediate needs and challenges following a diagnosis can help them cope and adjust well for better outcomes in the longer term.
Study From Atlantis Healthcare Shows Treatment Persistence and Adherence Improved by 38%
Monday, March 8, 2021
People living with nAMD experience a loss of central vision. As a result, many suffer significant psychological impact and a negative impact on quality of life including challenges with mobility, face recognition, day-to-day tasks, and self-care.
Impact of a Patient Support Program on Patient Beliefs About Neovascular Age-Related Macular Degeneration and Persistence to Anti-Vascular Endothelial Growth Factor Therapy
Friday, March 5, 2021
This published study compares treatment persistence between patients prescribed intravitreal aflibercept (IVT-AFL) for neovascular age-related macular degeneration (nAMD) in Australia who enrolled on the patient support program (PSP) designed and delivered by Atlantis Health with persistence in a 10% sample of patients from the Australian Pharmaceutical Benefits Scheme (PBS) dataset. Patients in the PSP showed 88% persistence after two years on treatment as compared to 64% persistence after two years in the PBS sample. PSP patients also showed improved beliefs about nAMD disease and its treatment over the course of the program.
Unique Challenges and Support Opportunities in Rare Disease
Sunday, February 28, 2021
In recognition of Rare Disease Day 2021, we highlight the rare and ultra-rare disease patient challenges and our experience and expertise in support solutions to help address the unique needs of people and their families living with rare disease. You can view the infographic here.